Project A Phase 2a study investigating the safety, pharmacokinetics, immunogenicity and exploratory efficacy of Dupilumab…

Basic data

Title:
A Phase 2a study investigating the safety, pharmacokinetics, immunogenicity and exploratory efficacy of Dupilumab in patients aged >6 to < 18 years with atopic dermatitis
Duration:
01/04/2015 to 01/04/2016
Abstract / short description:
A Phase 2a study investigating the safety, pharmacokinetics, immunogenicity and exploratory efficacy of Dupilumab in patients aged >6 to < 18 years with atopic dermatitis
Keywords:
dermatology
Dermatologie
children
Kinder
antibodies
Antikörper

Involved staff

Managers

Faculty of Medicine
University of Tübingen
Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine

Local organizational units

Department of Dermatology
Hospitals and clinical institutes
Faculty of Medicine

Funders

Tarrytown, New York, United States of America
Help

will be deleted permanently. This cannot be undone.